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moderate to high responsiveness according to OARSI criteria.After
3 weeks all subscales showed signiﬁcant improvements compared
to baseline (pain (p<0.001), stiffness (p<0.001) and function
(p<0.001)). No correlation where between the severity of OA
(K&L) and improvement in WOMAC score. The only variable (age,
gender, side, BMI, K&L, medial/lateral) which had a signiﬁcant
effect on WOMAC score was gender, women had higher score.
Quality of live during the study time improved according to EQ-5D.
Conclusions: Conclusions: An Unloading knee brace did de-
crease pain and improve function as shown by signiﬁcant im-
provement in WOMAC score for pain, stiffness, function and total
score. An Unloader brace is a treatment alternative even in mod-
erate and severe unicompartmental knee OA.
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Purpose: The aim of the study was to evaluate the clinical efﬁ-
cacy and safety of CG100649 administered in different dosages.
CG100649 is a ﬁrst-in-class NSAID candidate with a new mode
of “tissue-speciﬁc” activity designed to deliver sustained levels of
drug to inﬂamed tissues while maintaining low systemic exposure
by binding to carbonic anhydrase (CA) in red blood cells. Previous
Phase I clinical studies have shown that CG100649 has a unique
pharmacokinetic (PK) proﬁle with 85-100x higher concentrations
in whole blood (drug transport via erythrocytes that have high con-
centrations of CA) than in plasma (no CA). Synovial ﬂuid has been
shown to have little or no CA. Thus, CG100649 was hypothesized
to achieve maximum efﬁcacy in inﬂamed joints while minimizing
its impact on the cardio-renal system or GI tract.
Methods: Clinical trial CG100649-2-01 was a randomized, double-
blind study in male subjects, 18-75 years old, with a 3 month or
longer history of primary osteoarthritis (OA) of the hip or knee.
The study was conducted in 248 subjects at 25 investigative sites
in Germany, Hungary, and Ukraine. The trial was designed to
evaluate the safety and efﬁcacy of three parallel dose regimens of
CG100649 vs. placebo in the treatment of OA. After a 5-14 day
washout period from other pain relief medications, all doses were
administered orally, once a day in the morning. Initial loading doses
(Day 0) and maintenance doses (Days 1-20) were: High Dose (8
mg + 1.2 mg/day), Medium Dose (4 mg + 0.6 mg/day), and Low
Dose (2 mg + 0.3 mg/day). Subjects returned to the study center
once a week on Days 7, 14, and 21 during the treatment period
and on Days 28 and 35 during the follow-up period for safety and
efﬁcacy assessments. Efﬁcacy assessments included the Western
Ontario and McMaster Universities (WOMAC™) OA index, Brief
Pain Inventory (BPI), Subject’s Global Assessment, Physician’s
Global Assessment, withdrawals due to lack of efﬁcacy, and usage
of paracetamol (acetaminophen) as a rescue medication. Blood
pressure, ECG, and GI bleeding were monitored for potential
adverse side effects.
Results: The CG100649 high dose group showed more than a
2-fold greater magnitude of improvement than the placebo group
on the primary endpoint of change in the WOMAC score from
baseline to Day 21 (median values were 37% vs. 17%, respec-
tively; P=0.01). The study also met all key secondary endpoints,
with the high dose demonstrating clinically and statistically sig-
niﬁcant superiority over the placebo group in the WOMAC OA
score over the entire 21-day active treatment period (p=0.010)
and in the WOMAC subscales of pain, stiffness and physical
function (p=0.016, p=0.023, p=0.010, respectively) over the en-
tire 35-day treatment and follow-up evaluation periods. Weekly
pain relief scores showed statistically signiﬁcant improvements
at Days 7, 14, 21, and 28 (p<0.05 at all time periods) which
demonstrated that CG100649 had an early onset of activity and
provided sustained treatment beneﬁts over the entire treatment
period. No treatment-related changes were observed in systolic,
diastolic, or mean blood pressure in the entire subject population
or after controlling for age (younger vs. older subjects). No relevant
treatment group differences were noted for any other vital sign,
clinical laboratory parameter, ECG parameter. No subject experi-
enced gastrointestinal bleeding or other clinically relevant adverse
GI side effects.
Conclusions: These data provide the ﬁrst evidence of statistically
and clinically signiﬁcant analgesia and functional beneﬁts pro-
duced by a dual COX-2/CA inhibitor without meaningful GI and CV
side effects. All doses were well tolerated. Supported by a grant
from CrystalGenomics and partially supported from the BioStar
Program of MKE (Ministry of Knowledge Economy) of Korea.
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Purpose: Biomechanical studies of persons with medial
tibiofemoral OA demonstrate that even with appropriate valgus
knee bracing, large medial forces remain, suggesting that the
addition of other interventions to further improve limb alignment
may be of therapeutic value. The objective of this 30-week ran-
domized crossover trial was to determine whether a multi-modal
realignment therapy (consisting of valgus knee brace + motion
control shoes + neutral foot orthoses) would be successful in re-
lieving pain and improving function among persons with medial
tibiofemoral OA.
Methods: We conducted a double blind, randomized crossover
trial of a multi-modal realignment therapy for persons with me-
dial tibiofemoral OA. Trial participants met ACR criteria for OA
with knee pain, aching or stiffness on most of the past month
and radiographic evidence of a deﬁnite osteophyte. We tested
two different treatments: A) CONTROL TREATMENT consisting
of a neutral knee brace (no valgus angulation), ﬂat unsupportive
foot orthoses, and shoes with a ﬂexible midsole; and B) ACTIVE
TREATMENT consisting of a valgus knee brace, customized neu-
tral foot orthoses, and shoes designed for motion control. For
each subject, the trial lasted 30 weeks, including 12 weeks each
of active and control treatment separated by a 6-week washout pe-
riod. The primary outcome was change in knee pain and function
as assessed by the WOMAC Osteoarthritis Index (VAS version).
An unstructured correlation matrix for observations within subjects
was used in generalized estimating equation ﬁtting. The ﬁnal linear
regression model was conducted with exclusion of the differential
carryover effect.
Results: 80 participants with medial tibiofemoral OA were ran-
domized. 63% were female. Their mean age was 62 years and
mean BMI was 34 kg/m2. The main effects are depicted in Table 1.
There was no evidence of a carryover effect in the initial analyses.
